Insmed reported $45.37M in Sales Revenues for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acelrx Pharmaceuticals ACRX:US $ 0.44M 0.07M
Alexion Pharmaceuticals ALXN:US $ 1636.5M 44.7M
Alimera Sciences ALIM:US $ 21.7M 10.49M
Arena Pharmaceuticals ARNA:US $ 0M 0M
Biomarin Pharmaceutical BMRN:US $ 501.69M 15.66M
Cytokinetics CYTK:US $ 2.84M 3.7M
Dynavax Technologies DVAX:US $ 52.77M 30.57M
Flexion Therapeutics FLXN:US $ 28.17M 3.59M
Gilead Sciences GILD:US $ 6217M 206M
Heron Therapeutics HRTX:US $ 22.44M 2.42M
Insmed INSM:US $ 45.37M 5.15M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NVS:US $ 13294M 600M
Regeneron Pharmaceuticals REGN:US $ 5138.5M 2609.8M
Sarepta Therapeutics SRPT:US $ 164.09M 17.16M
Seattle Genetics SGEN:US $ 388.48M 56.5M
Ultragenyx Pharmaceutical RARE:US $ 86.98M 12.42M
Vertex Pharmaceuticals VRTX:US $ 1793.37M 69.06M